The deleterious effect of acetaminophen in cancer immunotherapy
- PMID: 35764272
- DOI: 10.1016/j.annonc.2022.06.012
The deleterious effect of acetaminophen in cancer immunotherapy
Conflict of interest statement
Disclosure RJS has served as a consultant and/or on scientific advisory boards for AstraZeneca, Bristol Myers Squibb, Iovance, Merck, Novartis, OncoSec, and Pfizer; and has also received research funding (provided to his institution) from Merck. PB has declared no conflicts of interest.
Comment on
-
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.Ann Oncol. 2022 Sep;33(9):909-915. doi: 10.1016/j.annonc.2022.05.010. Epub 2022 May 30. Ann Oncol. 2022. PMID: 35654248
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources